A Pharmacometric Approach to Quantify the Impact of Chronic Kidney Disease and Hemodialysis on Systemic Drug Exposure: Application to Saxagliptin

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

(2011) David W. Boulton et al.   CLINICAL PHARMACOKINETICS

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

(2011) M. Nowicki et al.   DIABETES OBESITY & METABOLISM

Application of Individualized Bayesian Urea Kinetic Modeling to Pediatric Hemodialysis

(2010) Olivera Marsenic et al.   ASAIO JOURNAL

Synergy Between Scientific Advancement and Technological Innovation, Illustrated by a Mechanism-Based Model Characterizing Sodium-Glucose Cotransporter-2 Inhibition

(2010) Liping Zhang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

In-Center Hemodialysis Six Times per Week versus Three Times per Week

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

(2009) Abd A. Tahrani et al.   ADVANCES IN THERAPY

Drug Dosing in Patients With Impaired Renal Function

(2009) D C Brater   CLINICAL PHARMACOLOGY & THERAPEUTICS

Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport

(2008) TD Nolin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications

(2008) Y Zhang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS